Arriving at the advisory committee review for Astellas Pharma Inc. and Cardiome Pharma Corp. ’s vernakalant (Kynapid) in December 2007, panel members found a new toy next to their microphone and tented name card: an electronic device in the shape of a small calculator.
The device, they were told, would be used at the end of the day-long meeting to record the committee’s votes. FDA was implementing new voting procedures under which members would...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?